AlloSource Celebrates 30 Years of Innovation
AlloSource, a prominent life sciences organization, is excited to celebrate three decades of impactful work transforming human tissue donations into life-enhancing medical products. Since its inception, AlloSource has been committed to restoring patient functionality and improving lives through its innovative approaches to utilizing human tissue.
Growth and Achievements Over Three Decades
Founded in 1994, AlloSource originally distributed around 14,000 allografts annually for surgical procedures. Fast forward to today, the organization has significantly scaled its operations, now providing over 200,000 allografts each year. This remarkable growth is a direct result of AlloSource's dedication to research and collaboration with surgical partners, leading to the development of groundbreaking products derived from human tissue.
Innovative Products
Throughout the last decade, AlloSource has introduced a variety of new products to meet the evolving needs of surgical specialties. Among these advancements are a specialized articular cartilage disc, amnion sheets, and dermal matrices for various applications. Recently, the launch of AceConnex Pre-Sutured Fascia marks a pivotal innovation as the first ready-to-use device aimed at repairing early hip labral damage.
Commitment to Donor Impact
AlloSource prides itself on its unique approach to sourcing materials for its products. Dr. Ross Wilkins, the Senior Medical Director at AlloSource, emphasizes the importance of honoring deceased tissue donors. Over the years, the organization has evolved from processing only a few donors monthly to now honoring thousands of donors each year, ensuring their contributions have a meaningful impact.
State-of-the-Art Facilities
The company operates from a spacious 160,000-square-foot headquarters equipped with 37 clean rooms for tissue processing and numerous laboratories. This high-tech facility allows AlloSource to maintain excellence in production, utilizing proprietary cryopreservation technology that facilitates the storage of fresh cartilage while preserving cell viability for up to two years.
Looking Ahead: Expanding Horizons
As part of its 30th-anniversary celebration, AlloSource is evolving its brand identity by incorporating the term 'Life Sciences' into its logo. This change is intended to highlight the organization's commitment to developing enhanced products for areas such as joint disease and women's health, particularly focusing on conditions like pelvic organ prolapse and breast reconstruction.
Core Values in Business
Dean Elliott, President and CEO of AlloSource, articulates the organization's foundational belief in the significance of human life, whether in its vitality or vulnerability. He stresses the potential that resides within the human body and expresses optimism about unlocking that potential through the ongoing dedication of AlloSource's staff.
About AlloSource
AlloSource is dedicated to enhancing patient health and functionality by transforming human tissue donations into advanced medical products. Partnering with medical professionals and biomedical companies, AlloSource aims for innovation and quality, serving a diverse marketplace globally since 1994. For more information about AlloSource, visit their official site.
Frequently Asked Questions
1. What does AlloSource celebrate this year?
AlloSource is celebrating its 30th anniversary of transforming human tissue donations into valuable medical products.
2. How many allografts does AlloSource provide annually?
AlloSource distributes over 200,000 allografts each year for various surgical applications.
3. What recent product has AlloSource launched?
AlloSource has recently launched AceConnex Pre-Sutured Fascia, a unique device to repair early hip labral damage.
4. Where is AlloSource headquartered?
The company is headquartered in a 160,000-square-foot facility equipped with advanced processing capabilities.
5. How does AlloSource honor tissue donors?
AlloSource ensures that each donor's influence is maximized by effectively utilizing their tissue for maximum impact in medical devices.
